A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration

This study is testing a new experimental drug called JAB-23E73 to see if it is safe and effective for treating adults with advanced solid tumors. It focuses on cancers with a specific genetic change known as a KRAS mutation, which helps researchers learn if this new medicine can successfully target and stop tumor growth.

You may be eligible if you are at least 18 years old and have an advanced cancer with a KRAS genetic mutation that has not responded to or cannot be treated by standard surgery. You must also be able to take oral medication and provide a previous sample of your tumor tissue for testing.

Participants will receive the experimental drug JAB-23E73 and be closely monitored by a medical team to check for side effects and see how the drug affects their cancer. You will need to visit the study center for regular check-ups and follow the study's medication schedule as instructed by your doctors.

The study is currently recruiting patients at medical centers in Rochester, Minnesota; St. Louis, Missouri; and Cleveland, Ohio. Please speak with your doctor or the study team at these locations to see if you qualify.